Literature DB >> 9453254

Transient virus infection and pathogenesis of a new HIV type 2 isolate, UC12, in baboons.

C P Locher1, D J Blackbourn, B G Herndier, G Reyes-Terán, S W Barnett, K K Murthy, J A Levy.   

Abstract

We have previously shown that baboons (Papio cynocephalus) can be persistently infected with HIV-2 and some baboons progress to an AIDS-like disease with a CD4+ T cell decline, cachexia, alopecia, and Kaposi's sarcoma-like fibromatosis. In this study, we found that a new virus isolate, HIV-2UC12, replicated to high levels in baboon peripheral blood mononuclear cells (PBMCs) in vitro. Three baboons were subsequently inoculated and had plasma viral RNA loads that peaked between 15,000 and 7000 copies/ml at 2 weeks postinfection. Virus was isolated from the PBMCs for up to 6 months. Although PBMCs were subsequently virus culture negative, virus could be recovered from the spleen, lymph nodes, and tonsils, indicating that HIV-2 was sequestered within these lymphoid tissues. HIV-2-associated pathology included follicular lysis, vascular proliferation, and lymphoid depletion. This study indicated that HIV-2UC12 infection in baboons can cause HIV-associated pathological abnormalities within the lymphatic tissues and that the high level of HIV-2UC12 replication in vitro was not predictive of replication in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453254     DOI: 10.1089/aid.1998.14.79

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons.

Authors:  Christopher P Locher; Stephanie A Witt; Brian G Herndier; Nancy W Abbey; Klara Tenner-Racz; Paul Racz; Nancy B Kiviat; Krishna K Murthy; Kathleen Brasky; Michelle Leland; Jay A Levy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas.

Authors:  Haihan Song; Emi E Nakayama; Masaru Yokoyama; Hironori Sato; Jay A Levy; Tatsuo Shioda
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

3.  Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5α-mediated restriction.

Authors:  Ken Kono; Haihan Song; Masaru Yokoyama; Hironori Sato; Tatsuo Shioda; Emi E Nakayama
Journal:  Retrovirology       Date:  2010-09-08       Impact factor: 4.602

4.  Clearance of a productive lentivirus infection in calves experimentally inoculated with caprine arthritis-encephalitis virus.

Authors:  Thierry Morin; François Guiguen; Baya Amel Bouzar; Stéphanie Villet; Timothy Greenland; Délphine Grezel; Françoise Gounel; Kathy Gallay; Céline Garnier; Jitka Durand; Théodore Alogninouwa; Laïla Mselli-Lakhal; Jean-François Mornex; Yahia Chebloune
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Novel Kaposi's sarcoma-associated herpesvirus homolog in baboons.

Authors:  Denise Whitby; Andrea Stossel; Christine Gamache; James Papin; Marnix Bosch; Anne Smith; Dean H Kedes; Gary White; Ronald Kennedy; Dirk P Dittmer
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  TRIM5α and Species Tropism of HIV/SIV.

Authors:  Emi E Nakayama; Tatsuo Shioda
Journal:  Front Microbiol       Date:  2012-01-24       Impact factor: 5.640

7.  Role of Human TRIM5α in Intrinsic Immunity.

Authors:  Emi E Nakayama; Tatsuo Shioda
Journal:  Front Microbiol       Date:  2012-03-15       Impact factor: 5.640

8.  Electrostatic potential of human immunodeficiency virus type 2 and rhesus macaque simian immunodeficiency virus capsid proteins.

Authors:  Katarzyna Bozek; Emi E Nakayama; Ken Kono; Tatsuo Shioda
Journal:  Front Microbiol       Date:  2012-06-05       Impact factor: 5.640

Review 9.  Impact of TRIM5α in vivo.

Authors:  Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS       Date:  2015-09-10       Impact factor: 4.177

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.